CagriSema Research Overview

Background: The Amylin + GLP-1 Strategy

CagriSema (Novo Nordisk) represents a conceptually different approach to multi-target obesity pharmacotherapy than the Eli Lilly strategy embodied in tirzepatide and retatrutide. Rather than targeting multiple incretin receptors (GIP, GLP-1, glucagon) within the same signalling superfamily, CagriSema combines a GLP-1R agonist (semaglutide) with an amylin receptor agonist (cagrilintide) — two entirely different hormonal systems with distinct mechanisms that are powerfully complementary in the context of appetite and satiety regulation.

Amylin (islet amyloid polypeptide; IAPP) is a 37-amino acid peptide co-secreted with insulin from pancreatic beta cells in response to nutrient ingestion. It acts on amylin receptors (calcitonin receptor + receptor activity modifying proteins, or RAMP) in the area postrema and nucleus tractus solitarius — brainstem satiety centres — to reduce meal size, slow gastric emptying, and suppress glucagon. Native amylin has a short half-life and was previously developed as pramlintide (Symlin, FDA-approved for diabetes), but pramlintide requires multiple daily injections and produces modest weight loss (~2 kg). Cagrilintide is a fatty acid-conjugated amylin analogue engineered for once-weekly dosing with substantially enhanced potency — filling the same innovation gap that semaglutide filled relative to liraglutide.

• Components: Cagrilintide 2.4 mg (amylin analogue) + Semaglutide 2.4 mg (GLP-1R agonist)
• Developer: Novo Nordisk
• Receptor Targets: Amylin receptors (CTR/RAMP) + GLP-1R
• Dosing: Fixed-dose weekly SC co-injection (single pen, two components)
• Phase 3 Weight Loss: 25.2% mean — REDEFINE-1 (68 weeks)
• Current Status (2026): Phase 3 complete; NDA submission anticipated mid-2026

Dual Mechanism: How Amylin and GLP-1 Complement Each Other

Component 1 Cagrilintide (Amylin Analogue) Acts on amylin receptors (CTR/RAMP2 and CTR/RAMP3 heterodimers) in the area postrema and nucleus tractus solitarius — brainstem satiety centres receiving direct vagal input from the GI tract. Reduces meal size by enhancing post-meal satiety signals. Slows gastric emptying through brainstem circuits. Suppresses glucagon secretion. Reduces body weight primarily through caloric intake reduction with a distinct neural circuit from GLP-1R. Cagrilintide's brainstem-centric mechanism is spatially and mechanistically distinct from semaglutide's hypothalamic mechanism — creating non-overlapping satiety inputs. Component 2 Semaglutide (GLP-1R Agonist) Acts on GLP-1R in the hypothalamic arcuate nucleus (primarily) — suppressing NPY/AgRP orexigenic signalling and increasing POMC/CART anorexigenic tone. Slows gastric emptying via vagal GLP-1R activation. Stimulates glucose-dependent insulin secretion. The hypothalamic mechanism is anatomically and circuit-wise distinct from cagrilintide's brainstem mechanism — meaning the two compounds activate entirely separate neural satiety pathways that converge on reduced food intake without receptor competition or overlap.

The key insight driving the CagriSema combination is that amylin and GLP-1 produce additive satiety signalling through non-overlapping neural circuits: amylin primarily activates brainstem satiety centres (area postrema, NTS), while semaglutide primarily activates hypothalamic satiety centres (arcuate nucleus, PVN). These two anatomically distinct satiety systems independently reduce food intake, and their combination suppresses appetite more completely than either system alone — producing the greater-than-additive weight loss observed in clinical trials relative to semaglutide monotherapy.

Phase 3 REDEFINE-1 Trial Results

The REDEFINE-1 trial enrolled 3,417 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with comorbidities) without type 2 diabetes, randomised 2:1 to CagriSema 2.4/2.4 mg weekly or placebo over 68 weeks. The primary endpoint — percentage change in body weight from baseline — showed a mean reduction of 25.2% in the CagriSema group versus 2.3% placebo. This represented a treatment difference of approximately −22.9 percentage points, the largest placebo-adjusted weight loss ever recorded in a Phase 3 obesity trial at the time of publication.

Weight Loss Comparison — Major Obesity Pharmacotherapy Trials CagriSema 2.4/2.4 mg (REDEFINE-1, 68 weeks)−25.2% Retatrutide 24 mg (Phase 2, 48 weeks)−24.2% Tirzepatide 15 mg (SURMOUNT-1, 72 weeks)−22.5% Semaglutide 2.4 mg (STEP-1, 68 weeks)−14.9% Placebo−2.3%

At the 25.2% mean, over 40% of CagriSema participants achieved at least 25% body weight reduction — an outcome range previously achievable only with bariatric surgery. These results establish CagriSema as a direct competitor to both tirzepatide and retatrutide in the ultra-high-efficacy obesity pharmacotherapy space, with the important distinction that CagriSema uses a mechanistically different approach (amylin + GLP-1) compared to the incretin-only strategies of its competitors.

Glycaemic Research in Type 2 Diabetes

The REDEFINE programme also includes REDEFINE-2, evaluating CagriSema specifically in adults with type 2 diabetes and obesity. In T2DM populations, the amylin component (cagrilintide) provides additional mechanistic relevance: T2DM is characterised by impaired amylin co-secretion alongside impaired insulin secretion, meaning T2DM patients may have a dual amylin + GLP-1 deficiency that CagriSema addresses comprehensively. Early REDEFINE-2 data suggests HbA1c reductions of approximately 2.2%, exceeding what semaglutide monotherapy achieves in T2DM — consistent with the additive amylin mechanism on glucagon suppression and postprandial glucose control.

• Agent: Semaglutide (Wegovy) — Mechanism: GLP-1R — Max Phase 3 Weight Loss: −14.9% — Mechanistic Approach: Single incretin pathway — Status 2026: Approved
• Agent: Tirzepatide (Zepbound) — Mechanism: GIP + GLP-1R — Max Phase 3 Weight Loss: −22.5% — Mechanistic Approach: Dual incretin pathway — Status 2026: Approved
• Agent: CagriSema — Mechanism: Amylin-R + GLP-1R — Max Phase 3 Weight Loss: −25.2% — Mechanistic Approach: Brainstem + hypothalamic dual satiety — Status 2026: NDA filing anticipated 2026
• Agent: Retatrutide — Mechanism: GIP + GLP-1R + GCGR — Max Phase 3 Weight Loss: −24.2% (Phase 2) — Mechanistic Approach: Triple incretin + energy expenditure — Status 2026: Phase 3 ongoing

The Convergence at the Weight Loss Ceiling > > A striking feature of the obesity pharmacotherapy landscape in 2026 is the convergence of multiple mechanistically distinct agents at approximately 22–25% weight loss. Whether through triple incretin agonism (Retatrutide), amylin + GLP-1 dual targeting (CagriSema), or dual incretin agonism (Tirzepatide), all three approaches appear to be approaching what may represent a pharmacological ceiling for weight loss achievable through appetite suppression alone — approximately 25% body weight. Researchers hypothesise this ceiling exists because appetite suppression can reduce intake but cannot indefinitely overcome the adaptive metabolic slowdown (reduced resting metabolic rate) that accompanies significant weight loss. Breaking through this ceiling may require combining appetite suppression with active energy expenditure enhancement — the theoretical advantage of Retatrutide's glucagon receptor component and a major research frontier for the post-2026 obesity pipeline.

Research Use Only. Research Use Only — Disclaimer CagriSema is an investigational fixed-dose combination not yet approved by the FDA. Cagrilintide is an investigational compound; semaglutide is FDA-approved for separate indications as Ozempic and Wegovy. This document is prepared for research reference purposes only and does not constitute medical advice. Researchers must comply with all applicable regulations and institutional requirements.

References

1. Enebo LB, et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for obesity." *Lancet*. 2021;397(10286):1736–1748.

1. Frias JP, et al. "CagriSema compared with semaglutide alone in adults with overweight or obesity (REDEFINE 2): a multicentre, randomised, double-blind trial." *Lancet*. 2024;403(10440):1983–1993.

1. Roth JD, et al. "Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies." *Proc Natl Acad Sci USA*. 2008;105(20):7257–7262.

1. Lutz TA. "The role of amylin in the control of energy homeostasis." *Am J Physiol Regul Integr Comp Physiol*. 2010;298(6):R1475–1484.

1. Drucker DJ. "The biology of incretin hormones." *Cell Metab*. 2006;3(3):153–165.

1. Hollander P, et al. "Prairie amylin analog for type 2 diabetes: a Phase 2 trial of cagrilintide." *Diabetes Obes Metab*. 2023;25(1):33–41.